New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial
The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial EUROPEAN RADIOLOGY Jamshidi, N., Jonasch, E., Zapala, M., Korn, R. L., Brooks, J. D., Ljungberg, B., Kuo, M. D. 2016; 26 (8): 2798-2807Abstract
To characterize a radiogenomic risk score (RRS), a previously defined biomarker, and to evaluate its potential for stratifying radiological progression-free survival (rPFS) in patients with metastatic renal cell carcinoma (mRCC) undergoing pre-surgical treatment with bevacizumab.In this IRB-approved study, prospective imaging analysis of the RRS was performed on phase II clinical trial data of mRCC patients (n?=?41) evaluating whether patient stratification according to the RRS resulted in groups more or less likely to have a rPFS to pre-surgical bevacizumab prior to cytoreductive nephrectomy. Survival times of RRS subgroups were analyzed using Kaplan-Meier survival analysis.The RRS is enriched in diverse molecular processes including drug response, stress response, protein kinase regulation, and signal transduction pathways (P?25 months (P?=?0.005) and overall survival of 25 versus >37 months in the high and low RRS groups (P?=?0.03), respectively. Conventional prognostic predictors including the Motzer and Heng criteria were not predictive in this cohort (P?>?0.05).The RRS stratifies rPFS to bevacizumab in patients from a phase II clinical trial with mRCC undergoing cytoreductive nephrectomy and pre-surgical bevacizumab.• The RRS SOMA stratifies patient outcomes in a phase II clinical trial. • RRS stratifies subjects into prognostic groups in a discrete or continuous fashion. • RRS is biologically enriched in diverse processes including drug response programs.
View details for DOI 10.1007/s00330-015-4082-8
View details for Web of Science ID 000379192500043
View details for PubMedID 26560727